期刊文献+

EITOP方案治疗复发和难治性非霍奇金淋巴瘤疗效分析 被引量:1

Effect of EITOP Regimen on Recurrent and Refractory Non-Hodgkin's lymphoma
下载PDF
导出
摘要 目的:探讨用足叶乙甙(VP-16,E)、异环磷酰胺(Ifosfamide,I)、吡柔比星(Pirarubicin,T)、长春新碱(VCR,O)、泼尼松(Prednisone,P)组成的EITOP方案治疗复发或难治非霍奇金淋巴瘤的疗效和毒性。方法:42例患者予EITOP方案治疗,异环磷酰胺1.2g.(m2)-1.d-1静脉滴注,d1~d5,吡柔比星30mg.(m2)-1.d-1静脉注射,d1~d3,长春新碱1.4mg.(m2)-1.d-1,静脉注射,d1,泼尼松40mg.(m2)-1.d-1口服,d1~d7,平均每3周为1周期,全组患者接受3个~8个周期治疗,平均4个周期。结果:42例患者接受EITOP方案化疗,完全缓解22例,部分缓解10例,总有效率76.19%,中位生存期为42个月,毒副作用主要为骨髓抑制。结论:EITOP方案是治疗复发或难治非霍奇金淋巴瘤的有效方案,毒性反应可耐受。 Objoctive To observe the effect and side effect s of EITOP regimen for patient s with recurrent and refractory Non-Hodgkin's lymphoma. Methods 60 mg.(m^2)^-1.d^-1 VP-16 (E) was administered iv by drop on dl,3,5; 1.2g.(m^2)^-1.d^-1Ifosfamide (IFO) iv by drop on dl-5 ; 30mg.(m^2)^-1.d^-1 Pirarubicin (THP)iv by drop on dl-3; 1.4 mg.(m^2)^-1.d^-1 VCR iv by drop on dl and 40mg.(m^2)^-1.d^-1 Prednisone was given on d1-7 .The mean of one chemotherapy period is 4 weeks,all the patients are obtained 3-10 periods'treatment while Mean is 4 weeks. Results In all 42 patient s, 22 CR and 10PR, 76.19%ofrespense rate was achieved. Main toxicities were neutropenia and thrombocytopenia.Conclusion EITOP regimen can achieve a satisfied result s in the treatment of recurrent and refractory Non-Hodgkin's lymphoma with well tolerated toxicity.
出处 《实用医技杂志》 2008年第2期152-154,共3页 Journal of Practical Medical Techniques
关键词 复发和难治性非霍奇金淋巴瘤 化疗 EITOP方案 Recurrent and refractory Non-Hodgkin's lymphoma Chemotherapy EITOP regimen
  • 相关文献

参考文献4

二级参考文献31

  • 1丁永为.序贯短程大剂量联合化疗治疗?60例恶性淋巴瘤[J].中华血液学杂志,1993,14(9):488-489. 被引量:2
  • 2勇威本,高非,孙红,白羽,王淑娴,刘彤.BCOPP/CHOP─B治疗非何杰金淋巴瘤疗效观察[J].北京医学,1995,17(2):65-68. 被引量:2
  • 3Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkins. N Engl J Med, 1993, 328(14): 1002 - 1006.
  • 4Moskowitz CH, Nimer SD, Glassman JR, et al. The International Prognostic Index predicts for outcome following ASCT in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant, 1999, 23(6): 561 - 567.
  • 5McCoy AG,Smith EP, Atkinson ME, et al. A novel preparative regimen for autologous transplant in non-Hodgkin' s lymphoma: long-term experience with etoposide and thiotepa. Bone Marrow Transplant, 2004,33(1): 19 -24.
  • 6Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin,and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-Cell mobilization regimen for transplant-eligible patients with non-Hodgkin' s lymphoma. J Clin Oncol, 1999, 17( 12): 3776 - 3785.
  • 7Sawada M,Tsurumi H,Yamada T,et al. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy[J]. Eur J Haematol,2002,68(6):
  • 8Shipp MA, Mauch PM, Harris NL. Non-Hodgkin's lymphomas[A]. In: Devita VT Jr, Hellmen S, Rosenberg SA, eds. Cancer, principles and practice of oncology[M].5ed. Philadelphia:New York :Lippincott-Raven. 1997:2165-2220.
  • 9Tirelli U, Errante D, Van GM, et al. CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of
  • 10Ezzat AA, Ibrahim EM, Stuart RK, et al. Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial[J]. Med Oncol,2000,17(1): 39-46.

共引文献51

同被引文献11

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部